This article is more than 5 years old. Information may no longer be current.
Fixed-dose combination reduces diurnal IOP better than individual components
Click Here to Manage Email Alerts
CORONADO, Calif. — A fixed-dose combination of IOP-lowering medications reduced diurnal IOP more effectively than its constituent components dosed individually, according to a scientific poster presented here.
Jason Bacharach, MD, and colleagues reported that PG324 ophthalmic solution (Aerie Pharmaceuticals) reduced IOP significantly more than either latanoprost or AR-13324 (Aerie) individually over a 1-month trial.
PG324 0.01% or 0.02% is a fixed-dose combination drug that comprises latanoprost 0.005% and AR-13324 0.01% or 0.02%. The randomized double-masked study included 298 patients with open-angle glaucoma or ocular hypertension. Seventy-four patients received PG324 0.01%, 73 received PG324 0.02%, 73 received latanoprost and 78 received AR-13324 0.02%.
The primary efficacy endpoint was mean diurnal IOP at 29 days. Secondary efficacy endpoints were mean IOP at 8 a.m., 10 a.m. and 4 p.m., and percentage of patients who achieved pre-specified reductions in IOP from baseline to 29 days.
PG324 0.02% reduced diurnal IOP significantly more than latanoprost and AR-13324 0.02% from baseline to day 29 (P < .0001).
PG324 reduced IOP significantly more than latanoprost and AR-13324 at all time points (PG324 3.2 mm Hg, latanoprost 1.6 mm Hg; PG324 3.4 mm Hg, AR-13324 1.7%; all P ≤ .001).
Fifty-seven percent of patients treated with PG324 and 29% of patients treated with latanoprost achieved mean diurnal IOP of 17 mm Hg or less.
The most common adverse event, transient asymptomatic conjunctival hyperemia, was typically mild.– by Matt Hasson and Patricia Nale, ELS
Disclosure: Bacharach reports financial relationships with Aerie Pharmaceuticals, Alcon, Allergan, Amakem, Glaukos, Lumenis, Oculus, Ono and Valeant/Bausch + Lomb.